Mineralys Therapeutics Q2 FY26 earnings call MLYS

Mineralys is systematically executing its commercial launch plan for lorundrostat, focusing on final readiness and execution ahead of the December 22 PDUFA date. The company has established relationships with hypertension specialists, engaged with payers covering the vast majority of US lives, and is developing a differentiated launch campaign. Management believes lorundrostat's clinical profile aligns well with physician expectations for meaningful and durable blood pressure reductions, favorable tolerability, and fit within existing treatment algorithms, addressing the 20 million US adults with uncontrolled or resistant hypertension.

During the quarter, Mineralys completed several strategic financial initiatives to enhance long-term value and financial flexibility. This included an agreement to repurchase future royalty payments for lorundrostat from Tanabe Pharma Corporation for $200 million upfront, with up to $100 million in commercial milestones. Concurrently, the company completed a $150 million equity offering and secured a $500 million committed senior secured term loan facility with Pharmakon Advisors, positioning Mineralys to capture the long-term value of lorundrostat and fund operations into 2028.

The Transform-HTN open-label extension trial continues to generate long-term safety and efficacy data. Post hoc analysis from the pivotal Launch-HTN trial, presented at the European Society of Hypertension, showed comparable blood pressure reductions in CKD patients and a 52% placebo-adjusted reduction in urine albumin to creatinine ratio. Late-breaking proteomic data from Launch-HTN and Advance-HTN, presented at ENDO 2026, demonstrated significant reductions in heart failure risk biomarkers. These findings strengthen the understanding of lorundrostat's potential benefits beyond blood pressure reduction, and the company continues to evaluate further clinical development.

Mineralys welcomed Dr. Terry Ferguson as Chief Medical Officer, bringing over 35 years of experience in cardiovascular medicine and clinical development. Dr. David Rodman, the previous CMO, will transition to a full-time strategic advisor role. This move is expected to augment the company's expertise in late-stage clinical activities and medical affairs, leveraging Dr. Ferguson's relationships with KOLs and Dr. Rodman's deep knowledge of lorundrostat's development, particularly in exploring translational opportunities for cardiorenal metabolic disorders.

Payer engagement activities have been positive, with payers recognizing the unmet need in uncontrolled hypertension. While early, the launch of Baxfendy (baxdrostat) indicates enthusiasm for the Aldosterone Synthase Inhibitor (ASI) class. Mineralys anticipates that both ASI agents will achieve equivalent payer access, allowing lorundrostat's differentiated profile (best-in-class blood pressure reduction, favorable safety/tolerability, and unique Advance-HTN data) to drive adoption. The company is finalizing its pricing strategy, aiming to maximize value while ensuring broad patient access.